IOmx Therapeutics
iOmx Therapeutics is a clinical-stage biotech company that develops cancer immunotherapies for solid tumor indications. The company utilizes its systematic screening platform, iOTarg, to identify novel immune checkpoint targets and translate immune evasion biology into biomarker-enabled drug programs. Its lead candidate, OMX-0407, is an orally available SIK inhibitor designed to prevent tumors from evading death receptor-mediated killing.
Biotech
Healthcare
Oncology
Funding summary
- Total raised
- €105.0M
- Funding rounds
- 2
Investors in IOmx Therapeutics
Investors on record for IOmx Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like IOmx Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors